文献类型：期刊文献

英文题名：Prognostic value of Interleukin-36s in cancers: A systematic review and meta-analysis

作者：Zhang, Rui[1,2,3];Jiang, Mengyuan[1,2,3];Huang, Min[1,2,3];Yang, Jing[1,2,3];Liu, Qianqian[1,2,3];Zhao, Ziru[1,2,3];Bai, Yuping[4];He, Tingting[1,2,3];Zhang, Dengcai[1,5];Zhang, Min[1,2,6]

第一作者：Zhang, Rui;张蕊

通信作者：Zhang, M[1]

机构：[1]Gansu Univ Tradit Chinese Med, Clin Med Coll 1, Lanzhou 730000, Gansu, Peoples R China;[2]Gansu Prov Hosp, Dept Pathol, Lanzhou 730000, Gansu, Peoples R China;[3]Chinese Peoples Liberat Army, Hosp Joint Logist Support Force 940, Dept Pathol, Lanzhou 730000, Gansu, Peoples R China;[4]Hainan Prov Hosp, Dept Pathol, Haikou 570100, Hainan, Peoples R China;[5]Gansu Prov Matern & Child Hosp, Dept Pathol, Lanzhou 730000, Gansu, Peoples R China;[6]Gansu Prov Hosp, Dept Sci Res Off, 160 Donggangxilu Rd, Lanzhou 730000, Gansu, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Prov Hosp, Dept Sci Res Off, 160 Donggangxilu Rd, Lanzhou 730000, Gansu, Peoples R China.

年份：2023

卷号：172

外文期刊名：CYTOKINE

收录：;Scopus(收录号：2-s2.0-85175243884);WOS:【SCI-EXPANDED(收录号:WOS:001108380100001)】；

基金：This work was supported by Science and Technology Program of Gansu Province: the basic research innovation group [grant NO. 22JR5RA709]; the research center of the molecular pathological diagnosis and technical engineering of Gansu province [grant NO. 2021GSFZBL01].

语种：英文

外文关键词：IL-36 alpha; IL-36 beta; IL-36 gamma; Cancer; Prognosis

摘要：Background: Interleukin-36s (IL-36s) are a category of inflammatory cytokines and an increasing number of studies over the past decade have found that different kinds of IL-36s play different roles in cancers. This systematic review and meta-analysis aimed to evaluate the prognostic value of IL-36s in different cancer types.Method: Two reviewers independently searched in PubMed, Cochrane Library and EMBASE up to December 13, 2022. We extracted the hazard ratio (HR) and the confidence intervals (CIs) of the related prognostic outcomes and analyzed the pooled HR.Results: We included 12 studies including 1925 patients. In all, six studies including IL-36 alpha, five including IL-36 gamma and one including IL-36 beta. A high expression of IL-36 alpha was associated with better overall survival (OS) (HR = 0.48, 95 %CI: 0.37-0.62, P < 0.001) of cancer patients. The expression of IL-36 gamma was not related with cancers. Further, subgroup analysis showed that the expression of IL-36 gamma had no correlation with the OS of colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients. Interestingly, a high expression of IL-36 gamma played contrasting prognostic roles in hepatocellular carcinoma (HCC) (HR = 0.43, 95 %CI: 0.27-0.69, P < 0.001) patients and gastric cancer (GC) (HR = 1.58, 95 %CI: 1.33-1.87, P < 0.001) patients. The only IL-36 beta related study showed the expression of IL-36 beta was not correlated with the prognosis of CRC patients (P > 0.05).Conclusion: IL-36 alpha, IL-36 beta and IL-36 gamma possibly play different roles in different cancers. High expression of IL-36 alpha may be associated with good prognostic value in cancer patients, especially in CRC patients. The association between cancers prognosis and expression of IL-36 beta or IL-36 gamma needs further evaluation. These conclusions need more clinical prognostic data for confirmation.